66 citations
,
December 2018 in “Dermatology” Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.
June 2025 in “Proceedings of the National Academy of Sciences” A PIK3CA mutation in Schwann cells causes severe nerve damage and increased glycolysis, but early treatment can help.
August 2019 in “bioRxiv (Cold Spring Harbor Laboratory)” The model successfully predicted new uses for existing drugs, like using certain hormonal and heart medications for respiratory and Parkinson's diseases, and a cancer drug for diabetes.
6 citations
,
February 2023 in “Journal of the American Academy of Dermatology” Upadacitinib improved hair regrowth and quality of life in alopecia areata patients with minimal side effects.
5 citations
,
February 2025 in “Pediatric Dermatology” Ritlecitinib was generally well tolerated in children with alopecia areata.
November 2008 in “Cancer Prevention Research” Chemoprevention can significantly lower cancer risks and needs more research and collaboration.
May 2025 in “Dermatology Online Journal” Erlotinib can cause excessive eyelash growth.
1 citations
,
May 1992 in “Pharmacological Research” 1 citations
,
January 2022 in “Journal of Cancer Therapy” Ocoxin improves quality of life for advanced ovarian cancer patients on chemotherapy.
July 2024 in “Open Repository of the University of Porto (University of Porto)” Dutasteride is more effective than finasteride for hair growth, and pregabalin effectively treats neuropathic pain.
July 2024 in “Journal of Investigative Dermatology” A KLK5 inhibitor effectively improved skin symptoms in a mouse model of Netherton Syndrome.
34 citations
,
February 2015 in “Frontiers in Cellular Neuroscience” Zebrafish helped find new ways to prevent drug-induced hair cell death and potential treatments for hearing loss.
2-Hydroxy-1,4-naphthoquinone is a strong 5α-reductase inhibitor.
November 2004 in “Oncology Times” Advocacy groups should avoid marketing partnerships that may imply drug endorsements.
May 2015 in “Cancer Research” A new treatment may prevent hair loss from chemotherapy by normalizing scalp cell death and reducing inflammation.
September 2015 in “Photodiagnosis and Photodynamic Therapy” 117 citations
,
August 1999 in “Nature Genetics” March 2025 in “European Journal of Medical Genetics” Tofacitinib helped improve symptoms and hair growth in a patient with Aicardi-Goutières syndrome.
Baricitinib works better than methotrexate for severe alopecia areata.
December 2024 in “Naunyn-Schmiedeberg s Archives of Pharmacology”
69 citations
,
February 2021 in “PLoS Computational Biology” Securinine and ajmaline may effectively treat liver cancer, with securinine being less toxic to normal cells.
6 citations
,
January 2020 in “International Journal of Biological Sciences” Septin4 helps kill colon cancer cells by working with the protein BAX.
February 2017 in “Cancer Research” Topical calcitriol appears safe and may reduce hair loss during chemotherapy.
November 2023 in “British Journal of Dermatology” Different people with severe hair loss respond to baricitinib treatment at different times, with some showing improvement early, some gradually, and others later.
June 2014 in “Dermatology Times E-News” An arthritis drug helped a person with severe hair loss regrow their hair.
June 2025 in “British Journal of Dermatology” Ruxolitinib helped a woman with a genetic mutation regrow her hair and improved her health.
May 2024 in “Journal of cosmetic dermatology” Tofacitinib is an effective and safe treatment for alopecia areata.
5 citations
,
January 1991 in “Drugs of The Future” 355 citations
,
January 2017 in “Journal of the American Academy of Dermatology” JAK inhibitors show promise for treating skin conditions like eczema, hair loss, and psoriasis.
August 2021 in “The journal of investigative dermatology/Journal of investigative dermatology” TAGX-0003 protected hair follicles and reversed alopecia areata in a mouse model.